WGU D027 – ADVANCED PATHOPHARMACOLOGICAL
FOUNDATIONS PRE-ASSESSMENT COMPLETE QUESTION BANK: 350
QUESTIONS WITH DETAILED ANSWERS AND RATIONALES 2026 LATEST
UPDATE – FULLY REVISED AND EXPANDED EDITION
PART 1 – CELLULAR REGULATION, GENETICS & IMMUNOLOGY
Questions 1–50
Topics:
1–5: Cellular injury, necrosis, apoptosis
6–12: Neoplasia, oncogenes, tumor suppressors, cellular adaptations
13–19: Genetic inheritance patterns and chromosomal disorders
20–25: Genetic hematologic disorders (CF, sickle cell, thalassemia, hemophilia, VWD)
26–33: Hypersensitivity reactions and immunoglobulins
34–39: MHC, T cells, B cells, NK cells, complement
40–45: Inflammation, acute phase reactants, fever, wound healing
46–50: Free radical injury, reperfusion, metaplasia/dysplasia, carcinogenesis
PART 2 – CARDIOVASCULAR & HEMATOLOGIC DISORDERS
Questions 51–100
Topics:
51–55: MI, biomarkers, STEMI management, angina, nitrates
56–65: Statins, ACE inhibitors, beta-blockers, diuretics, heart failure, digoxin
66–73: Calcium channel blockers, anticoagulants, heparin, warfarin, DOACs
74–80: Antiplatelets, hypertension, spironolactone, ARNI
81–90: Anemias, B12/folate, CKD anemia, sickle cell, hydroxyurea, ITP, DIC
91–100: Aplastic anemia, hemophilia, statins/fibrates, familial hypercholesterolemia, valvular
disease, endocarditis
PART 3 – RESPIRATORY & RENAL DISORDERS
Questions 101–150
Topics:
101–110: Asthma, COPD, pneumonia
111–120: TB, PE, ARDS, pneumothorax, chronic bronchitis/emphysema
121–125: Theophylline, cystic fibrosis, dornase alfa
126–135: AKI, CKD, nephrotic/nephritic syndrome, UTIs, pyelonephritis
136–143: BPH, kidney stones, gout, SIADH, DI, electrolytes
144–150: Calcium, acid-base disorders
PART 4 – ENDOCRINE, GASTROINTESTINAL & NUTRITIONAL DISORDERS
Questions 151–200
Topics:
1
,151–162: Diabetes mellitus, DKA, HHS, metformin, sulfonylureas, insulin, hypoglycemia
163–175: Thyroid disorders, Cushing, Addison, hyperaldosteronism, pheochromocytoma,
DI/SIADH
176–185: GERD, PPI, H. pylori, IBD, cirrhosis, pancreatitis
186–200: Celiac, lactose intolerance, vitamin deficiencies, obesity, metabolic syndrome, thyroid
meds, SGLT2/GLP-1, beta-blockers in cirrhosis
PART 5 – NEUROLOGIC, MUSCULOSKELETAL & SENSORY DISORDERS
Questions 201–250
Topics:
201–205: Stroke, TIA, thrombolytics
206–213: Epilepsy, phenytoin, ethosuximide, status epilepticus, Parkinson, Alzheimer
214–220: Myasthenia gravis, MS, GBS, spinal cord injury, autonomic dysreflexia
221–230: ICP, mannitol, migraine, osteoporosis, RA, gout, osteoarthritis
231–240: NSAIDs, glaucoma, macular degeneration, cataract, Meniere, otitis media, valproate,
carbamazepine
241–250: Bell palsy, shingles, meningitis, head/spinal injury, topiramate, osteoporosis, RA
biologics, hip fracture
PART 6 – INFECTIOUS DISEASE, ONCOLOGY & MULTISYSTEM DISORDERS
Questions 251–300
Topics:
251–260: Antibiotics, vancomycin, aminoglycosides, fluoroquinolones, metronidazole, C. diff,
TB, HIV
261–270: HIV ART, neutropenia, chemo antiemetics, filgrastim, opioids, tumor lysis syndrome
271–280: Breast/prostate/colorectal cancer, cardiotoxicity, nephrotoxicity, neutropenic
precautions, myeloma, leukemia, lymphoma
281–290: Sepsis, shock states, DIC, transplant immunosuppression, GVHD
291–300: SLE, fibromyalgia, chronic fatigue, sickle cell, hemophilia, VWD, gout, rasburicase
PART 7 – MULTISYSTEM, EMERGENCY & PROFESSIONAL PRACTICE
Questions 301–350
Topics:
301–310: MODS, sepsis, heat stroke, frostbite, bites, burns, radiation
311–320: Bioterrorism, botulism, Ebola, nerve agents, antidotes
321–330: Antidotes, DEA, informed consent, off-label use, medication errors, high-alert meds
331–340: Renal/hepatic dosing, pregnancy/lactation, pediatric/geriatric, Beers Criteria, falls
341–350: Medication avoidance in HF, asthma, diabetes, glaucoma, BPH, CKD, cirrhosis,
angioedema, QT prolongation, narrow therapeutic index
2
,PART 1
QUESTION 1
A patient suffers an acute myocardial infarction. The ischemic myocardial tissue
demonstrates preserved tissue architecture, loss of nuclei, and intensely
eosinophilic cytoplasm. This pattern of cell death is best classified as:
A. Liquefactive necrosis
B. Coagulative necrosis
C. Caseous necrosis
D. Fat necrosis
Correct Answer: B. Coagulative necrosis
Rationale: Coagulative necrosis is characteristic of ischemic injury in solid organs
(except the brain). Tissue architecture is preserved while proteins denature,
nuclei are lost, and cytoplasm becomes eosinophilic. Liquefactive necrosis occurs
in brain infarcts and abscesses. Caseous necrosis occurs in tuberculosis. Fat
necrosis occurs in acute pancreatitis and breast trauma.
QUESTION 2
A patient with a bacterial brain abscess shows complete tissue destruction with
pus formation and loss of all cellular detail. This type of necrosis is:
A. Coagulative necrosis
B. Liquefactive necrosis
C. Caseous necrosis
D. Gangrenous necrosis
Correct Answer: B. Liquefactive necrosis
Rationale: Liquefactive necrosis results from enzymatic digestion by neutrophils,
producing liquid pus in abscesses and cerebral infarctions. Coagulative necrosis
preserves tissue architecture in ischemic solid organs. Caseous necrosis produces
cheese-like debris in granulomas. Gangrenous necrosis describes ischemic
necrosis of a limb.
3
, QUESTION 3
The extrinsic pathway of apoptosis is initiated when:
A. Mitochondrial membrane permeability increases and cytochrome c is released
B. Extracellular death ligands (FasL, TNF) bind to cell surface death receptors
C. Endoplasmic reticulum stress activates caspase-12
D. DNA damage activates p53 and Bax translocation
Correct Answer: B. Extracellular death ligands (FasL, TNF) bind to cell surface
death receptors
Rationale: The extrinsic apoptosis pathway is triggered by death ligands binding to
transmembrane death receptors (Fas, TNFR1), activating caspase-8. Option A
describes the intrinsic mitochondrial pathway. Option C describes ER stress-
mediated apoptosis. Option D describes p53-mediated intrinsic signaling.
QUESTION 4
A breast biopsy reveals a well-circumscribed, encapsulated mass with uniform,
well-differentiated cells, low mitotic activity, and no vascular invasion. These
features are most consistent with:
A. Malignant carcinoma with early metastasis
B. Benign neoplasm
C. Anaplastic transformation
D. Invasive ductal carcinoma
Correct Answer: B. Benign neoplasm
Rationale: Benign neoplasms are typically encapsulated, well-differentiated, slow-
growing, and non-metastasizing. Malignant tumors are invasive, poorly
differentiated, and capable of metastasis. Anaplasia refers to loss of
differentiation.
QUESTION 5
4
FOUNDATIONS PRE-ASSESSMENT COMPLETE QUESTION BANK: 350
QUESTIONS WITH DETAILED ANSWERS AND RATIONALES 2026 LATEST
UPDATE – FULLY REVISED AND EXPANDED EDITION
PART 1 – CELLULAR REGULATION, GENETICS & IMMUNOLOGY
Questions 1–50
Topics:
1–5: Cellular injury, necrosis, apoptosis
6–12: Neoplasia, oncogenes, tumor suppressors, cellular adaptations
13–19: Genetic inheritance patterns and chromosomal disorders
20–25: Genetic hematologic disorders (CF, sickle cell, thalassemia, hemophilia, VWD)
26–33: Hypersensitivity reactions and immunoglobulins
34–39: MHC, T cells, B cells, NK cells, complement
40–45: Inflammation, acute phase reactants, fever, wound healing
46–50: Free radical injury, reperfusion, metaplasia/dysplasia, carcinogenesis
PART 2 – CARDIOVASCULAR & HEMATOLOGIC DISORDERS
Questions 51–100
Topics:
51–55: MI, biomarkers, STEMI management, angina, nitrates
56–65: Statins, ACE inhibitors, beta-blockers, diuretics, heart failure, digoxin
66–73: Calcium channel blockers, anticoagulants, heparin, warfarin, DOACs
74–80: Antiplatelets, hypertension, spironolactone, ARNI
81–90: Anemias, B12/folate, CKD anemia, sickle cell, hydroxyurea, ITP, DIC
91–100: Aplastic anemia, hemophilia, statins/fibrates, familial hypercholesterolemia, valvular
disease, endocarditis
PART 3 – RESPIRATORY & RENAL DISORDERS
Questions 101–150
Topics:
101–110: Asthma, COPD, pneumonia
111–120: TB, PE, ARDS, pneumothorax, chronic bronchitis/emphysema
121–125: Theophylline, cystic fibrosis, dornase alfa
126–135: AKI, CKD, nephrotic/nephritic syndrome, UTIs, pyelonephritis
136–143: BPH, kidney stones, gout, SIADH, DI, electrolytes
144–150: Calcium, acid-base disorders
PART 4 – ENDOCRINE, GASTROINTESTINAL & NUTRITIONAL DISORDERS
Questions 151–200
Topics:
1
,151–162: Diabetes mellitus, DKA, HHS, metformin, sulfonylureas, insulin, hypoglycemia
163–175: Thyroid disorders, Cushing, Addison, hyperaldosteronism, pheochromocytoma,
DI/SIADH
176–185: GERD, PPI, H. pylori, IBD, cirrhosis, pancreatitis
186–200: Celiac, lactose intolerance, vitamin deficiencies, obesity, metabolic syndrome, thyroid
meds, SGLT2/GLP-1, beta-blockers in cirrhosis
PART 5 – NEUROLOGIC, MUSCULOSKELETAL & SENSORY DISORDERS
Questions 201–250
Topics:
201–205: Stroke, TIA, thrombolytics
206–213: Epilepsy, phenytoin, ethosuximide, status epilepticus, Parkinson, Alzheimer
214–220: Myasthenia gravis, MS, GBS, spinal cord injury, autonomic dysreflexia
221–230: ICP, mannitol, migraine, osteoporosis, RA, gout, osteoarthritis
231–240: NSAIDs, glaucoma, macular degeneration, cataract, Meniere, otitis media, valproate,
carbamazepine
241–250: Bell palsy, shingles, meningitis, head/spinal injury, topiramate, osteoporosis, RA
biologics, hip fracture
PART 6 – INFECTIOUS DISEASE, ONCOLOGY & MULTISYSTEM DISORDERS
Questions 251–300
Topics:
251–260: Antibiotics, vancomycin, aminoglycosides, fluoroquinolones, metronidazole, C. diff,
TB, HIV
261–270: HIV ART, neutropenia, chemo antiemetics, filgrastim, opioids, tumor lysis syndrome
271–280: Breast/prostate/colorectal cancer, cardiotoxicity, nephrotoxicity, neutropenic
precautions, myeloma, leukemia, lymphoma
281–290: Sepsis, shock states, DIC, transplant immunosuppression, GVHD
291–300: SLE, fibromyalgia, chronic fatigue, sickle cell, hemophilia, VWD, gout, rasburicase
PART 7 – MULTISYSTEM, EMERGENCY & PROFESSIONAL PRACTICE
Questions 301–350
Topics:
301–310: MODS, sepsis, heat stroke, frostbite, bites, burns, radiation
311–320: Bioterrorism, botulism, Ebola, nerve agents, antidotes
321–330: Antidotes, DEA, informed consent, off-label use, medication errors, high-alert meds
331–340: Renal/hepatic dosing, pregnancy/lactation, pediatric/geriatric, Beers Criteria, falls
341–350: Medication avoidance in HF, asthma, diabetes, glaucoma, BPH, CKD, cirrhosis,
angioedema, QT prolongation, narrow therapeutic index
2
,PART 1
QUESTION 1
A patient suffers an acute myocardial infarction. The ischemic myocardial tissue
demonstrates preserved tissue architecture, loss of nuclei, and intensely
eosinophilic cytoplasm. This pattern of cell death is best classified as:
A. Liquefactive necrosis
B. Coagulative necrosis
C. Caseous necrosis
D. Fat necrosis
Correct Answer: B. Coagulative necrosis
Rationale: Coagulative necrosis is characteristic of ischemic injury in solid organs
(except the brain). Tissue architecture is preserved while proteins denature,
nuclei are lost, and cytoplasm becomes eosinophilic. Liquefactive necrosis occurs
in brain infarcts and abscesses. Caseous necrosis occurs in tuberculosis. Fat
necrosis occurs in acute pancreatitis and breast trauma.
QUESTION 2
A patient with a bacterial brain abscess shows complete tissue destruction with
pus formation and loss of all cellular detail. This type of necrosis is:
A. Coagulative necrosis
B. Liquefactive necrosis
C. Caseous necrosis
D. Gangrenous necrosis
Correct Answer: B. Liquefactive necrosis
Rationale: Liquefactive necrosis results from enzymatic digestion by neutrophils,
producing liquid pus in abscesses and cerebral infarctions. Coagulative necrosis
preserves tissue architecture in ischemic solid organs. Caseous necrosis produces
cheese-like debris in granulomas. Gangrenous necrosis describes ischemic
necrosis of a limb.
3
, QUESTION 3
The extrinsic pathway of apoptosis is initiated when:
A. Mitochondrial membrane permeability increases and cytochrome c is released
B. Extracellular death ligands (FasL, TNF) bind to cell surface death receptors
C. Endoplasmic reticulum stress activates caspase-12
D. DNA damage activates p53 and Bax translocation
Correct Answer: B. Extracellular death ligands (FasL, TNF) bind to cell surface
death receptors
Rationale: The extrinsic apoptosis pathway is triggered by death ligands binding to
transmembrane death receptors (Fas, TNFR1), activating caspase-8. Option A
describes the intrinsic mitochondrial pathway. Option C describes ER stress-
mediated apoptosis. Option D describes p53-mediated intrinsic signaling.
QUESTION 4
A breast biopsy reveals a well-circumscribed, encapsulated mass with uniform,
well-differentiated cells, low mitotic activity, and no vascular invasion. These
features are most consistent with:
A. Malignant carcinoma with early metastasis
B. Benign neoplasm
C. Anaplastic transformation
D. Invasive ductal carcinoma
Correct Answer: B. Benign neoplasm
Rationale: Benign neoplasms are typically encapsulated, well-differentiated, slow-
growing, and non-metastasizing. Malignant tumors are invasive, poorly
differentiated, and capable of metastasis. Anaplasia refers to loss of
differentiation.
QUESTION 5
4
